Lyell Immunopharma (LYEL) Projected to Announce Earnings on Tuesday

Key Points

• Lyell Immunopharma is expected to report Q3 2026 results on November 10, with analysts projecting a loss of $2.06 per share and revenue of approximately $0.01 million.
• The company previously reported a quarterly loss of $1.92 per share, slightly better than the consensus estimate of a $1.94 loss, while revenue was effectively zero. Analysts expect full-year and next-year losses of $7.16 and $7.21 per share, respectively.
• LYEL shares recently traded at $11.11, well below the consensus analyst price target of $40.86; despite mixed ratings, the stock carries a “Moderate Buy” consensus as Lyell continues developing T-cell therapies for cancer.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is expected to be posting its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($2.06) per share and revenue of $0.01 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts' consensus estimates of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. On average, analysts expect Lyell Immunopharma to post ($7.16) EPS for the current fiscal year and ($7.21) EPS for the next fiscal year.

Lyell Immunopharma Stock Up 2.1%

NASDAQ LYEL traded up $0.23 during trading on Tuesday, reaching $11.11. 12,095 shares of the stock traded hands, compared to its average volume of 132,635. The firm has a market cap of $272.14 million, a price-to-earnings ratio of -0.87 and a beta of -0.03. The stock's 50-day moving average price is $10.93 and its 200 day moving average price is $16.83. Lyell Immunopharma has a fifty-two week low of $7.20 and a fifty-two week high of $45.00.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LYEL. Citigroup restated a "market outperform" rating on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial began coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They issued a "buy" rating and a $44.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Lyell Immunopharma in a research note on Thursday, October 15th. HC Wainwright reaffirmed a "buy" rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Finally, Stifel Nicolaus initiated coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a "buy" rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Lyell Immunopharma currently has an average rating of "Moderate Buy" and a consensus price target of $40.86.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell's research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.